| Unique ID issued by UMIN | UMIN000063661 |
|---|---|
| Receipt number | R000072835 |
| Scientific Title | Long-Term Changes in Corneal Endothelial Cell Density Following Endoscope-Guided PreserFlo MicroShunt Implantation in the Ciliary Sulcus in Eyes with Glaucoma: A Prospective Observational Study Including an Exploratory Comparison With Anterior Chamber Implantation |
| Date of disclosure of the study information | 2026/11/17 |
| Last modified on | 2026/11/17 09:58:19 |
A Five-Year Observational Study of Corneal Endothelial Cell Changes After PreserFlo MicroShunt Implantation in the Ciliary Sulcus in Patients With Glaucoma
PreserFlo Sulcus Study
Long-Term Changes in Corneal Endothelial Cell Density Following Endoscope-Guided PreserFlo MicroShunt Implantation in the Ciliary Sulcus in Eyes with Glaucoma: A Prospective Observational Study Including an Exploratory Comparison With Anterior Chamber Implantation
Sulcus-PFM ECD Study
| Japan |
Glaucoma
| Ophthalmology |
Others
NO
The primary objective of this prospective observational study is to evaluate long-term changes in corneal endothelial cell density (ECD) from baseline to 60 months after endoscope-guided PreserFlo MicroShunt implantation in the ciliary sulcus in eyes with glaucoma. ECD will be assessed in nine corneal regions, including the central region and eight peripheral regions, to determine the absolute change and percentage reduction at 60 months. As a secondary exploratory objective, longitudinal changes in ECD will be compared with those in eyes undergoing conventional anterior chamber implantation.
Safety
Percentage reduction and absolute change from baseline to 60 months in the equally weighted mean corneal endothelial cell density (ECD) across nine corneal regions (the central region and eight peripheral regions) following PreserFlo MicroShunt implantation in the ciliary sulcus.
Eyes with technically successful ciliary sulcus implantation will be analyzed. ECD measurements obtained at baseline and 3, 6, 12, 18, 24, 36, 48, and 60 months postoperatively will be analyzed using a linear mixed-effects model. The primary estimate will be the percentage reduction in ECD at 60 months.
1. ECD: Absolute and percentage changes in each of nine corneal regions from baseline to 60 months; regional differences; annual changes in the equally weighted nine-region mean ECD from 6 to 60 months; and comparison of primary sulcus implantation with sulcus reimplantation.
2. Exploratory comparison with anterior chamber implantation: Nine-region mean ECD trajectories, absolute and percentage changes at 60 months, regional ECD changes, and corneal events. Only primary implantations will be compared, using overlap weighting to adjust for baseline characteristics.
3. Low baseline ECD: Associations between baseline ECD and postoperative ECD changes; ECD trajectories in eyes with baseline ECD of 1000 cells/mm2 or less; incidence and timing of corneal edema, endothelial decompensation, corneal transplantation, central ECD below 500 cells/mm2, and unmeasurable ECD due to corneal damage through 60 months.
4. IOP and glaucoma treatment: IOP, IOP reduction, and medication counts at baseline and 1, 3, 6, 12, 18, 24, 36, 48, and 60 months; additional glaucoma surgery and its timing.
5. Visual function and OCT: Visual acuity through 60 months; visual field mean deviation at baseline and 12, 24, 36, 48, and 60 months; macular GCC and peripapillary RNFL thickness at baseline and 3, 6, 12, 18, 24, 36, 48, and 60 months; and macular OCT morphology.
6. Anterior segment OCT: Tube position at 1 month, bleb morphology at 3 months, and their associations with IOP reduction.
7. Surgical feasibility and safety: Technical success and conversion rates among all attempted sulcus implantations; associations of surgical techniques with success and complications; intraoperative and postoperative complications, additional procedures, glaucoma surgery, tube removal, and corneal events through 60 months.
Observational
| 18 | years-old | <= |
| Not applicable |
Male and Female
Patients who meet all of the following criteria will be eligible:
1. Patients diagnosed with glaucoma at Toyama University Hospital who are scheduled to undergo PreserFlo MicroShunt implantation in the ciliary sulcus or anterior chamber as part of routine clinical care.
2. Patients aged 18 years or older at the time of surgery.
3. Patients undergoing the eligible surgery during the study period after ethics committee approval.
4. Patients with at least one valid preoperative corneal endothelial cell density (ECD) measurement among nine corneal regions, including the central region and eight peripheral regions.
5. Patients who provide written informed consent for study participation before surgery.
The sulcus group will include both primary implantation and sulcus reimplantation following previous anterior chamber implantation. The anterior chamber group will generally include primary implantation cases. Combined cataract surgery will be permitted. If both eyes are eligible, only the first eye undergoing the eligible surgery during the study period will be included in the analysis.
Patients meeting any of the following criteria will be excluded:
1. Patients in whom preoperative corneal endothelial cell density (ECD) cannot be measured in any of the nine corneal regions, including the central region and eight peripheral regions.
2. Patients who do not provide written informed consent for participation in the study.
3. Patients considered unsuitable for participation by the principal investigator or other study investigators for medical or study-related reasons.
480
| 1st name | Atsushi |
| Middle name | |
| Last name | Hayashi |
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama
Department of Ophthalmology
930-0194
2630 Sugitani, Toyama City
0764347367
ahayashi@med.u-toyama.ac.jp
| 1st name | Mitsuya |
| Middle name | |
| Last name | Otsuka |
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama
Department of Ophthalmology
930-0194
2630 Sugitani, Toyama City
0764347363
otsuka@med.u-toyama.ac.jp
University of toyama
University of Toyama
Other
Research Ethics Committee for Clinical and Epidemiological Research of Toyama University
2630 Sugitani, Toyama City
0764158857
rinri@adm.u-toyama.ac.jp
NO
| 2026 | Year | 11 | Month | 17 | Day |
Unpublished
Preinitiation
| 2026 | Year | 10 | Month | 10 | Day |
| 2026 | Year | 11 | Month | 13 | Day |
| 2026 | Year | 12 | Month | 01 | Day |
| 2036 | Year | 03 | Month | 31 | Day |
This is a single-center, two-cohort, prospective observational study conducted at Toyama University Hospital. Patients with glaucoma undergoing PreserFlo MicroShunt implantation in the ciliary sulcus or anterior chamber as part of routine clinical care will be enrolled. Surgical indications and tube placement locations will be determined by the treating surgeons independently of study participation. No study-related allocation, additional examinations, or therapeutic interventions will be performed.
The target sample size is 480 patients (480 eyes), comprising 240 patients with technically successful ciliary sulcus implantation and 240 patients undergoing anterior chamber implantation. Patients will be followed for up to 60 months after surgery. Cases in which sulcus implantation is attempted but converted to anterior chamber implantation or another procedure will be recorded separately for the assessment of technical success and safety, without being counted toward either target cohort.
The sulcus group will include primary implantation and sulcus reimplantation following removal of a previously implanted anterior chamber device. Exploratory comparisons with the anterior chamber group will be restricted to primary implantation cases, with adjustment for baseline characteristics using overlap weighting.
Ciliary sulcus implantation of the PreserFlo MicroShunt is an off-label procedure, and separate informed consent for the surgery will be obtained independently of research participation consent. An exploratory interim analysis of outcomes through 12 months is planned, while the final analysis of the primary outcome will use data through 60 months.
| 2026 | Year | 11 | Month | 17 | Day |
| 2026 | Year | 11 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072835